SPOTLIGHT: Brain cancer vaccine doubles survival time

An experimental brain cancer vaccine more than doubled the survival time of patients suffering from glioblastoma multiforme. Early-stage data demonstrated that patients lived almost three years after taking the vaccine for a disease that typically kills people after one year. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.